Product Description
Innocare is developing ICP-B02, a CD3 x CD20 for hematology. (Sourced from: https://www.innocarepharma.com/media/1602/innocare-interim-ndr_en_2021829_final-de.pdf)
Mechanisms of Action: CD20 Antagonist,CD3 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innocare Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin